Last10K.com

Iovance Biotherapeutics, Inc. (IOVA) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

Iovance Biotherapeutics, Inc.

CIK: 1425205 Ticker: IOVA

Exhibit 99.1

 

 

 

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

 

 

SAN CARLOS, Calif., May 5, 2020 -- 

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020 financial results and provided a corporate update.

 

“We continue making strong progress toward commercializing Iovance TIL for melanoma and cervical cancer indications,” said Maria Fardis, Ph.D., MBA, Iovance President and Chief Executive Officer. “While COVID-19 has impacted healthcare systems globally, we have been able to continue our key business operations due to dedication from our employees and through close collaboration with our clinical sites and other business partners. Cancer patients are still in critical need of access to therapy and a one-time treatment may offer an attractive therapeutic option to patients and treating physicians. With the first potential cell therapy in solid tumors and a broad TIL platform, Iovance remains well-positioned to become the leader in development, manufacturing, and commercialization of TIL cell therapy for cancer.”

 

First Quarter 2020 Updates

 

Clinical:

·Melanoma: the last patient in the pivotal Cohort 4 of C-144-01 melanoma study was dosed in January 2020. The enrollment of this cohort was completed approximately three months ahead of schedule with over-enrollment due to increased demand for participation.
·Cervical: enrollment in the cervical study C-145-04 continues and completion of enrollment in the pivotal program is on track for approximately mid-2020.

 

Regulatory:

·Iovance continues preparing for submission of a Biologics License Application (BLA) in late 2020 through data compilation as well as internal readiness activities.

 

Manufacturing:

·Manufacturing at all manufacturing organizations continues as planned for ongoing clinical studies.
·Construction of the Iovance manufacturing facility at the Navy Yard in Philadelphia continues with initiation of the build of clean rooms in April 2020, ahead of schedule.

 

Corporate:

·Iovance continues to build a strong team with approximately 190 employees across multiple locations and an experienced commercial team in place preparing for launch of lifileucel.
·Iovance has been granted or allowed a total of 12 patents for compositions and methods of treatment in using Iovance TIL in a board range of cancers related to its 22-day second generation (Gen 2) manufacturing process.

 


The following information was filed by Iovance Biotherapeutics, Inc. (IOVA) on Tuesday, May 5, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Iovance Biotherapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Iovance Biotherapeutics, Inc..

Continue

Assess how Iovance Biotherapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Iovance Biotherapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Other
Filter Subcategory:
All
Income
Expense
Cash Flow
Debt
Other
Inside Iovance Biotherapeutics, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Loss
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Stockholders' Equity
Balance Sheet Components
Balance Sheet Components (Details)
Balance Sheet Components (Tables)
Cash Equivalents And Short-Term Investments
Cash Equivalents And Short-Term Investments (Details)
Cash Equivalents And Short-Term Investments (Tables)
Cash Equivalents And Short-Term Investments - Cost And Fair Value (Details)
Cash Equivalents And Short-Term Investments - Short-Term Investments (Details)
General Organization And Business
General Organization And Business (Details)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Company's Right-Of-Use Asset And Lease Liabilities (Details)
Leases - Components Of Lease Expenses (Details)
Leases - Maturities Of The Company's Operating Lease Liabilities (Details)
Legal Proceedings
Legal Proceedings (Details)
Licenses And Agreements
Licenses And Agreements (Details)
Related Party Transactions
Related Party Transactions (Details Textual)
Stock Based Compensation
Stock Based Compensation (Tables)
Stock Based Compensation - Additional Information (Details)
Stock Based Compensation - Assumptions (Details)
Stock Based Compensation - Stock Options (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Cash, Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Fair Value (Details)
Summary Of Significant Accounting Policies - Loss Per Share (Details)
Summary Of Significant Accounting Policies - Stock-Based Compensation By Instrument (Details)
Summary Of Significant Accounting Policies - Stock-Based Compensation Expense (Details)

Material Contracts, Statements, Certifications & more

Iovance Biotherapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IOVA
CIK: 1425205
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-20-056994
Submitted to the SEC: Tue May 05 2020 5:17:08 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, March 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/iova/0001104659-20-056994.htm